Skip to content

In the News

Long DNA for Difficult Applications – Dan Lin-Arlow, CEO

    CEO Dan Lin-Arlow discusses Ansa’s groundbreaking de novo synthesis of the world’s longest oligo and their proprietary method in a podcast with Theral Timpson on the Mendelspod podcast. Explore the challenges of synthesizing long DNA, the impact of computation and AI in DNA synthesis, and more. Subscribe to Mendelspod to listen to the full podcast.

    DNA Supplier Ansa Biotechnologies Snares $68 Million

      “Venture capitalists have supplied $68 million in fresh capital to Ansa Biotechnologies Inc., a startup that says it has developed a new way to produce DNA needed to develop medicines and other products made through genetic engineering.”

      ”Emeryville, Calif.-based Ansa says it has technology for writing genetic code that relies on enzymes instead of chemicals that current vendors use. This will enable faster and more accurate production of genetic material, especially for long sequences of DNA, which will be vital as demand for genetic material expands, Ansa backers said.”

      Read the full article.

      Enzymatic DNA Synthesis Challenges the Gold Standard

        In a GEN article, Julianna LeMieux discusses the challenge posed by enzymatic synthesis to the gold standard of DNA synthesis, phosphoramidite chemistry. Ansa CEO Dan Lin-Arlow shares insights on using TdT polymerase to achieve longer DNA, encouraging the pursuit of bold visions in DNA writing.

        Ansa Biotechnologies collaborates with Microsoft Research to help unlock scalable and sustainable DNA data writing technology

          “Synthetic DNA, at its root a tiny storer of information, offers a potential pathway toward significantly reducing the amount of space and material needed for future archival storage needs… DNA can be incredibly durable and can last thousands of years, unlike tape, which needs to be rewritten every 30 years at best.”

          ”We’re also working with Ansa Biotechnologies to develop a set of enzymatic reagents that are specifically tailored for our electrochemical array. We are always interested in learning about new chemistries and other technology that could make DNA data storage more sustainable.”

          Read the full article.

          Ansa Biotechnologies Awarded NSF SBIR Phase II Grant

            Building from a successful Phase I, Ansa will continue to develop and scale its enzymatic method for DNA synthesis with support from the National Science Foundation. Ansa’s technology enables a new DNA manufacturing process that promises to provide synthetic DNA to researchers in record time, accelerating biotechnology broadly.

            Enzymatic DNA synthesis enters new phase

              “But more generally, these short sequences are just a stepping stone toward being able to generate the long sequences that are currently out of reach with chemical synthesis. ‘We’re trying to make thousand-mers and make those into genes,’ says Arlow. Beyond synthetic biology, this could also help accelerate the production of nucleic acid-based vaccines or generate the lengthy strands of DNA needed for targeted rewriting of the genome with CRISPR through homology-directed recombination.”

              Read the full article.